The results of the phase III ClarIDHy trial have led to US FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations.

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis / Rimini, Margherita; Burgio, Valentina; Antonuzzo, Lorenzo; Rimassa, Lorenza; Oneda, Ester; Lavacchi, Daniele; Personeni, Nicola; Ratti, Francesca; Pedica, Federica; Della Corte, Angelo; Persano, Mara; De Cobelli, Francesco; Aldrighetti, Luca; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea. - In: TARGETED ONCOLOGY. - ISSN 1776-2596. - 17:5(2022), pp. 591-596. [10.1007/s11523-022-00917-7]

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis

Rimini, Margherita;Ratti, Francesca;Pedica, Federica;Della Corte, Angelo;De Cobelli, Francesco;Aldrighetti, Luca;Cascinu, Stefano;Casadei-Gardini, Andrea
2022-01-01

Abstract

The results of the phase III ClarIDHy trial have led to US FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations.
2022
Bile Ducts, Intrahepatic
Glycine
Humans
Isocitrate Dehydrogenase
Mutation
Pyridines
Bile Duct Neoplasms
Cholangiocarcinoma
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/132337
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact